Does your elderly (>65 years of age) patient with type 2 diabetes meet one or more of the following criteria:

- At risk of hypoglycemia (e.g. due to advancing age, tight glycemic control, multiple comorbidities, drug interactions, hypoglycemia history or unawareness, impaired renal function, or on sulfonylurea or insulin)
- Experiencing, or at risk of, adverse effects from antihyperglycemic agents
- Uncertainty of clinical benefit (due to: frailty, dementia or limited life-expectancy)

- Set individualized A1C and blood glucose (BG) targets (otherwise healthy with 10+ years life expectancy, A1C < 7% appropriate; considering advancing age, frailty, comorbidities and time-to-benefit, A1C < 8.5% and BG < 180mg/dL¹ may be acceptable; at end-of-life, individualize BG target to avoid symptoms and complications from glycemic management)

- Address potential contributors to hypoglycemia (e.g. not eating, drug interactions such as trimethoprim/sulfamethoxazole and sulfonylurea, recent cessation of drugs causing hyperglycemia – see reverse)

- Reduce dose(s) or stop agent(s)
  - most likely to contribute to hypoglycemia (e.g. sulfonylurea, insulin; strong recommendation from systematic review and GRADE approach)ᵇ or other adverse effects (good practice recommendation)ᶜ

- Switch to an agent
  - with lower risk of hypoglycemia (e.g. switch from glyburide to glipizide⁹ or non-sulfonylurea; change NPH or mixed insulin to a long-acting basal insulin analog* to reduce nocturnal hypoglycemia; strong recommendation from systematic review and GRADE approach)ᵇ

- Reduce doses
  - of renally eliminated antihyperglycemics (e.g. metformin, sitagliptin; good practice recommendation)ᶜ – See guideline for recommended dosing

Monitor daily for 1-2 weeks after each change (TZD – up to 12 weeks)
- For signs of hyperglycemia (excessive thirst or urination, fatigue)
- For signs of hypoglycemia and/or resolution of adverse effects related to antihyperglycemic(s)

Increase frequency of blood glucose monitoring if needed
A1C changes may not be seen for several months

If hypoglycemia continues and/or adverse effects do not resolve:
- Reduce dose further or try another deprescribing strategy

If symptomatic hyperglycemia or blood glucose exceeds individual target:
- Return to previous dose or consider alternate drug with lower risk of hypoglycemia

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.

This work is licensed under a Creative Commons Attribution-Noncommercial-ShareAlike 4.0 International License. Contact deprescribing@bruyere.org or visit deprescribing.org for more information.


October 2018: Algorithm modified by the Endocrine Society and Avalere Health in accordance with the Bruyère Deprescribing Guidelines Research Team’s Modification Policy. Original materials available at https://tinyurl.com/yag638uz.

¹ modifications conform to ADA guideline targets, American measurement units, and drug availability
ᵇ see guideline publication for description
ᶜ based on clinical/expert consensus
Antihyperglycemics and Hypoglycemia Risk

<table>
<thead>
<tr>
<th>Drug</th>
<th>Causes hypoglycemia?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitor</td>
<td>No</td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 (DPP-4) inhibitors</td>
<td>No</td>
</tr>
<tr>
<td>Glucagon-like peptide-1 (GLP-1) agonists</td>
<td>No</td>
</tr>
<tr>
<td>Insulin</td>
<td>Yes (highest risk with regular insulin and NPH insulin)</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>Yes (low risk)</td>
</tr>
<tr>
<td>Metformin</td>
<td>No</td>
</tr>
<tr>
<td>Sodium-glucose linked transporter 2 (SGLT2) inhibitors</td>
<td>No</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>Yes (highest risk with glyburide and glimepride and lower risk with glipizide)</td>
</tr>
<tr>
<td>Thiazolidinediones (TZDs)</td>
<td>No</td>
</tr>
</tbody>
</table>

**Drugs affecting glycemic control**

- Drugs reported to cause hyperglycemia (when these drugs stopped, can result in hyperglycemia from antihyperglycemic drugs) e.g. quinolones (especially gatifloxacin), beta-blockers (except carvedilol), thiazides, atypical antipsychotics (especially olanzapine and clozapine), corticosteroids, calcineurin inhibitors (such as cyclosporine, sirolimus, tacrolimus), protease inhibitors
- Drugs that interact with antihyperglycemics (e.g. trimethoprim/sulfamethoxazole with sulfonylureas)
- Drugs reported to cause hypoglycemia (e.g. alcohol, MAOIs, salicylates, quinolones, quinine, beta-blockers, ACEIs, pentamidine)

**Engaging patients and caregivers**

- Some older adults prefer less intensive therapy, especially if burdensome or increases risk of hypoglycemia
- Patients and/or caregivers may be more likely to engage in discussion about changing targets or considering deprescribing if they understand the rationale:
  - Risks of hypoglycemia and other side effects
  - Risks of tight glucose control (no benefit and possible harm with A1C (< 6.5%)\(^a\))
  - Time to benefit of tight glucose control
  - Reduced certainty about benefit of treatment with frailty, dementia or at end-of-life
- Goals of care: avoid hyperglycemic symptoms (thirst, dehydration, frequency, falls, fatigue, renal insufficiency) and prevent complications (5-10 years of treatment needed)
- Many countries agree on less aggressive treatment of diabetes in older persons
- Reviewing options for deprescribing, as well as the planned process for monitoring and thresholds for returning to previous doses will help engage patients and caregivers

**Hypoglycemia information for patients and caregivers**

- Older frail adults are at higher risk of hypoglycemia
- There is a greater risk of hypoglycemia with tight control
- Symptoms of hypoglycemia include: sweating, tachycardia, tremor BUT older patients may not typically have these
- Cognitive or physical impairments may limit older patient’s ability to respond to hypoglycemia symptoms
- Some drugs can mask the symptoms of hypoglycemia (e.g. beta blockers)
- Harms of hypoglycemia may be severe and include: impaired cognitive and physical function, falls and fractures, seizures, emergency room visits and hospitalizations

**Tapering advice**

- Set blood glucose & A1C targets, plus thresholds for returning to previous dose, restarting a drug or maintaining a dose
- Develop tapering plan with patient/caregiver (no evidence for one best tapering approach; can stop oral antihyperglycemics, switch drugs, or lower doses gradually e.g. changes every 1-4 weeks, to the minimum dose available prior to discontinuation, or simply deplete patient’s supply)
- Doses may be increased or medication restarted any time if blood glucose persists above individual target\(^b\) or symptomatic hyperglycemia returns

\(^a\) modifications conform to ADA guideline targets, American measurement units, and drug availability
\(^b\) see guideline publication for description
\(^c\) based on clinical/expert consensus